By Joe Petroziello — Pharmaceutical Executive
June 13, 2024
Novel approaches against chronic inflammation could potentially prevent certain inflammatory diseases and neurological conditions.
During BIO International Convention 2024, CEO Dave Bearss, PhD, of Halia Therapeutics, discussed the biopharmaceutical company’s progress in chronic inflammation therapy and drug discovery. Founded in 2017, Halia Therapeutics supports the discovery and development of novel therapies to improve the lives of patients with inflammatory disorders and neurological diseases.